Cell surface markers for mesenchymal stem cells related to the skeletal system: A scoping review

Fonseca, Luisa  Nathalia; Bolívar-Moná, Santiago; Agudelo, Tatiana; Beltrán, Liz  Daniela; Camargo, Daniel; Correa, N. Mariano; Castillo, María Alexandra Del; Castro, Sebastián Fernández de; Fula, Valeria; García, Gabriela; Guarnizo, Natalia; Lugo, Valentina; Martínez, Liz  Mariana; Melgar, Verónica; Peña, María Clara; Pérez, Wilfran  Arbey; Rodríguez, Nicolás; Pinzón, Andrés; Albarracín, Sonia Luz; Olaya, Mercedes; Gutiérrez-Gómez, María Lucía

doi:10.1016/j.heliyon.2023.e13464

Cited by 11 publications

(10 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, negative markers (CD34, CD45, CD11b, CD19, and HLA-DR) exhibited very low or no expression, with positive rates less than or equal to 0.2%. Similar findings were made by Fonseca et al, [27].…”

Section: Discussionsupporting

confidence: 92%

“…3B shows that the hUCMSCs employed in this test had a positive expression rate mean greater than 98% for CD73, CD90, and CD105, while the positive expression rate for CD34, CD14, CD45, CD19, and HLA-DR was ≦0.2%. These outcomes are altogether consistent with previous research [27]. Positive expression was determined to be ≥95% for CD73, CD90, and CD105, and ≤2% for CD34, CD45, CD14, CD19, and HLA-DR.…”

Section: Detection Of Cell Phenotype and Surface Characteristic Markerssupporting

confidence: 91%

See 1 more Smart Citation

Isolation, Biological Characterization, and Quality Inspection of Human Umbilical Cord-derived Mesenchymal Stem Cells for Clinical Research

Zuo,

Dongcheng,

et al. 2024

AJBGMB

View full text Add to dashboard Cite

Background: Human umbilical cord mesenchymal stem cells (hUCMSCs) represent a valuable and versatile cell type derived from the umbilical cord tissue of newborns. These cells exhibit diverse characteristics, including multipotent differentiation potential and low immunogenicity. hUCMSCs hold promise for clinical applications, yet concerns persist regarding their chromosomal stability. This study employs short tandem repeat (STR) analysis to assess genomic integrity. By focusing on chromosomal stability, the study aims to enhance confidence in the clinical viability of hUCMSCs, contributing to their safe and effective use in regenerative medicine. hUCMSCs were extracted from healthy newborn umbilical cords using tissue block adherence and enzyme digestion. The third generation of hUCMSCs undergoes biological characterization and quality checks, including examinations of cell morphology, viability, growth curves, surface markers, cell cycle, and multi-lineage differentiation potential. The result of the present study shows that hUCMSCs exhibit mesenchymal stem cell characteristics, with robust growth and high viability. Positive surface markers are expressed at rates exceeding 95%, while negative markers are ≤2%. Cell karyotyping analysis, STR spectrum identification, and chromosomal microarray analysis confirm genetic stability. Microbial testing shows the absence of contaminants, and immunological studies demonstrate the immunomodulatory capabilities of hUCMSCs. Specific residues, such as trypsin, were not detected. In conclusion, hUCMSCs produced under strict GLP and GMP conditions meet the quality guidelines for clinical application in various stem cell therapies. The findings support the clinical application of hUCMSCs in various medical contexts.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Detection Of Cell Phenotype and Surface Characteristic Markerssupporting

confidence: 91%

Isolation, Biological Characterization, and Quality Inspection of Human Umbilical Cord-derived Mesenchymal Stem Cells for Clinical Research

Zuo,

Dongcheng,

et al. 2024

AJBGMB

View full text Add to dashboard Cite

show abstract

“…It is well established that culturing MSCs in 3D enhances their multilineage potential compared to 2D cultures [ 76 ]. Our transcriptomics analysis revealed an increased expression of CD44, an MSC stemness marker [ 77 ], while genes related to osteogenic and adipogenic differentiation, such as osteopontin (SPP1), bone morphogenetic protein-2 (BMP-2), and FOXO1, which have been linked with pro-osteogenic functions [ 78 – 80 ], showed a significant increase in their expression when MSCs were cultured in 3D (Fig. 6 G).…”

Section: Resultsmentioning

confidence: 99%

Fabrication of a three-dimensional bone marrow niche-like acute myeloid Leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system

Alhattab,

Isaioglou,

Alshehri

et al. 2023

Biomater Res

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is a hematological malignancy that remains a therapeutic challenge due to the high incidence of disease relapse. To better understand resistance mechanisms and identify novel therapies, robust preclinical models mimicking the bone marrow (BM) microenvironment are needed. This study aimed to achieve an automated fabrication process of a three-dimensional (3D) AML disease model that recapitulates the 3D spatial structure of the BM microenvironment and applies to drug screening and investigational studies. Methods To build this model, we investigated a unique class of tetramer peptides with an innate ability to self-assemble into stable hydrogel. An automated robotic bioprinting process was established to fabricate a 3D BM (niche-like) multicellular AML disease model comprised of leukemia cells and the BM’s stromal and endothelial cellular fractions. In addition, monoculture and dual-culture models were also fabricated. Leukemia cell compatibility, functionalities (in vitro and in vivo), and drug assessment studies using our model were performed. In addition, RNAseq and gene expression analysis using TaqMan arrays were also performed on 3D cultured stromal cells and primary leukemia cells. Results The selected peptide hydrogel formed a highly porous network of nanofibers with mechanical properties similar to the BM extracellular matrix. The robotic bioprinter and the novel quadruple coaxial nozzle enabled the automated fabrication of a 3D BM niche-like AML disease model with controlled deposition of multiple cell types into the model. This model supported the viability and growth of primary leukemic, endothelial, and stromal cells and recapitulated cell-cell and cell-ECM interactions. In addition, AML cells in our model possessed quiescent characteristics with improved chemoresistance attributes, resembling more the native conditions as indicated by our in vivo results. Moreover, the whole transcriptome data demonstrated the effect of 3D culture on enhancing BM niche cell characteristics. We identified molecular pathways upregulated in AML cells in our 3D model that might contribute to AML drug resistance and disease relapse. Conclusions Our results demonstrate the importance of developing 3D biomimicry models that closely recapitulate the in vivo conditions to gain deeper insights into drug resistance mechanisms and novel therapy development. These models can also improve personalized medicine by testing patient-specific treatments. Graphical Abstract

show abstract

“…MSCs may display a range of surface molecules and cellular cytokines according to where they originated from. CD45, CD34, CD19, CD14, CD11b, CD79, and HLA‐DR are not expressed, making CD90, CD73, and CD105 the most common markers that identify MSCs 95–98 . Several studies show that MSCs may be new way to treat DFU by improving angiogenesis and re‐epithelialization, helping to control the immune system, reducing inflammatory processes, and repairing DFU 17 …”

Section: Stem Cell Therapymentioning

confidence: 99%

“…CD45, CD34, CD19, CD14, CD11b, CD79, and HLA‐DR are not expressed, making CD90, CD73, and CD105 the most common markers that identify MSCs. 95 , 96 , 97 , 98 Several studies show that MSCs may be new way to treat DFU by improving angiogenesis and re‐epithelialization, helping to control the immune system, reducing inflammatory processes, and repairing DFU. 17 …”

Section: Stem Cell Therapymentioning

confidence: 99%

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Hetta,

Elsaghir,

Sijercic

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundDiabetes has evolved into a worldwide public health issue. One of the most serious complications of diabetes is diabetic foot ulcer (DFU), which frequently creates a significant financial strain on patients and lowers their quality of life. Up until now, there has been no curative therapy for DFU, only symptomatic relief or an interruption in the disease's progression. Recent studies have focused attention on mesenchymal stem cells (MSCs), which provide innovative and potential treatment candidates for several illnesses as they can differentiate into various cell types. They are mostly extracted from the placenta, adipose tissue, umbilical cord (UC), and bone marrow (BM). Regardless of their origin, they show comparable features and small deviations. Our goal is to investigate MSCs' therapeutic effects, application obstacles, and patient benefit strategies for DFU therapy.MethodologyA comprehensive search was conducted using specific keywords relating to DFU, MSCs, and connected topics in the databases of Medline, Scopus, Web of Science, and PubMed. The main focus of the selection criteria was on English‐language literature that explored the relationship between DFU, MSCs, and related factors.Results and DiscussionNumerous studies are being conducted and have demonstrated that MSCs can induce re‐epithelialization and angiogenesis, decrease inflammation, contribute to immunological modulation, and subsequently promote DFU healing, making them a promising approach to treating DFU. This review article provides a general snapshot of DFU (including clinical presentation, risk factors and etiopathogenesis, and conventional treatment) and discusses the clinical progress of MSCs in the management of DFU, taking into consideration the side effects and challenges during the application of MSCs and how to overcome these challenges to achieve maximum benefits.ConclusionThe incorporation of MSCs in the management of DFU highlights their potential as a feasible therapeutic strategy. Establishing a comprehensive understanding of the complex relationship between DFU pathophysiology, MSC therapies, and related obstacles is essential for optimizing therapy outcomes and maximizing patient benefits.

show abstract

Cell surface markers for mesenchymal stem cells related to the skeletal system: A scoping review

Cited by 11 publications

References 154 publications

Isolation, Biological Characterization, and Quality Inspection of Human Umbilical Cord-derived Mesenchymal Stem Cells for Clinical Research

Isolation, Biological Characterization, and Quality Inspection of Human Umbilical Cord-derived Mesenchymal Stem Cells for Clinical Research

Fabrication of a three-dimensional bone marrow niche-like acute myeloid Leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Contact Info

Product

Resources

About